BrainStorm Cell Therapeutics Inc.’s Outstanding ALS Clinical Data Chosen to Kick-Off the Israel Neurological Association Meeting

Published: Dec 11, 2012

NEW YORK & PETACH TIKVA, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is proud to announce that its positive Phase I/II ALS clinical trial data was selected as the opening presentation of the prestigious Israel Neurological Association’s Annual Meeting, which will convene on December 12, 2012 in Jerusalem, Israel. The data, regarding the first 12 ALS patients in the trial, will be presented by Principal Investigator Dr. Dimitrios Karussis, MD, of the Neurology Department at Hadassah Medical Center in Jerusalem, Israel.

Back to news